Clinical Trials List
Protocol Number20220028
Active
2024-05-15 - 2030-12-31
Phase I
Recruiting2
ICD-10C19
Malignant neoplasm of rectosigmoid junction
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9154.0
Malignant neoplasm of rectosigmoid junction
-
Trial Applicant
IQVIA RDS Taiwan Ltd.
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/02/01
Investigators and Locations
Co-Principal Investigator
- Yi-Ping Hung Division of Hematology & Oncology
- Hao-Wei Teng Division of Hematology & Oncology
- Mu-Hsin Chang Division of Hematology & Oncology
- Muh-Hwa Yang Division of Hematology & Oncology
- Jiun-I Lai Division of Hematology & Oncology
- 姜乃榕 Division of Hematology & Oncology
- San-Chi Chen Division of Hematology & Oncology
- Ta-Chung Chao Division of Hematology & Oncology
- Chueh-Chuan Yen Division of Hematology & Oncology
- Chien-An Liu Division of Radiology
- Tien-Hua Chen Division of Hematology & Oncology
- Chun-Yu Liu Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 吳宗哲 Division of Hematology & Oncology
- 許嘉林 Division of General Internal Medicine
- 廖唯昱 Division of General Internal Medicine
- 吳尚俊 Division of General Internal Medicine
- JIN-YUAN SHIH Division of General Internal Medicine
- James Chih-Hsin Yang Division of Hematology & Oncology
- 廖斌志 Division of Hematology & Oncology
- Jih-Hsiang Lee Division of Hematology & Oncology
- 徐偉勛 Division of Hematology & Oncology
- 楊景堯 Division of General Internal Medicine
- 蔡子修 Division of General Internal Medicine
- CHAO-CHI HO CHAO-CHI HO Division of General Internal Medicine
- YEN-TING LIN Division of General Internal Medicine
- 梁逸歆 Division of Hematology & Oncology
- Kun-Huei Yeh Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
30 participants
-
Global
535 participants
